CliffBio
small molecule

DICLOFENAC SODIUM

DICLOFENAC SODIUM

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameDICLOFENAC SODIUM
Active ingredientDICLOFENAC SODIUM
Strength1%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusOTC

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DICLOFENAC SODIUM patent cliff — loss of exclusivity — | CliffBio